Comparison of iron supplementation methods for hemodialysis patients

Comparison of iron supplementation methods for hemodialysis patients - Comparison of iron supplementation methods for hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017366

Enrollment

300

Registered

2015-05-01

Start date

2014-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage kidney disease

Interventions

Intravenous administration of 40mg of saccharated ferric oxide once a week after hemodialysis Oral administration of 50-100mg of sodium ferrous citrate per day Ferric citrate hydrate group: oral admin

6.0mg/dL) are registered.]

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients complicated with iron deficiency (transferrin saturation < 20% and ferritin < 100 ng/mL) or hyperphosphatemia

Exclusion criteria

Exclusion criteria: Patients complicated with potential diseases causing anemia such as hemorrhagic disease, hematological disease, or carcinoma

Design outcomes

Primary

Measure	Time frame
Changes in hemoglobin values of before and after the iron supplementation and the frequency of side effect by iron supplementation	—

Secondary

Measure	Time frame
Changes in values of serum iron, transferrin saturation, ferritin, and the amount of administered erythropoiesis-stimulating agents	—

Countries

Japan

Contacts

Public ContactMichio Kuwahara

Shuuwa General Hospital Department of Nephrology

kuwaharam@shuuwa-gh.or.jp048-737-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026